

Alan W Partin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10661753/publications.pdf>

Version: 2024-02-01

356
papers

38,109
citations

3874

91
h-index

3688

186
g-index

359
all docs

359
docs citations

359
times ranked

21835
citing authors

#	ARTICLE	IF	CITATIONS
1	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
2	A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use. <i>World Journal of Urology</i> , 2021, 39, 1845-1851.	1.2	3
3	Complications after open and robotâ€ assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial. <i>BJU International</i> , 2021, 127, 190-197.	1.3	6
4	Contemporary Assessment of the Most Cited Clinical, Basic Science, and Guidelines Papers in Urology: A Reference for Urology Journal Club. <i>Urology</i> , 2021, 149, 58-69.	0.5	4
5	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 220-232.	2.0	3
6	Advances in the selection of patients with prostate cancer for active surveillance. <i>Nature Reviews Urology</i> , 2021, 18, 197-208.	1.9	21
7	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 247-247.	0.8	0
8	Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0245530.	1.1	21
9	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.2	21
10	Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. <i>Journal of Urology</i> , 2021, 205, 1681-1688.	0.2	3
11	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	0.9	22
12	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. <i>BJU International</i> , 2020, 125, 861-866.	1.3	19
13	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3182-3192.	3.2	64
14	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 470-475.e1.	0.9	26
15	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cellâ€ Based Drug Delivery. <i>Stem Cells Translational Medicine</i> , 2019, 8, 739-740.	1.6	1
16	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. <i>Stem Cells Translational Medicine</i> , 2019, 8, 441-449.	1.6	50
17	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediateâ€ risk to veryâ€ highâ€ risk clinically localised prostate cancer. <i>BJU International</i> , 2019, 124, 268-274.	1.3	36
18	Adjuvant radiation with androgenâ€ deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. <i>BJU International</i> , 2019, 123, 252-260.	1.3	34

#	ARTICLE	IF	CITATIONS
19	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16575-e16575.	0.8	0
20	Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. Urology, 2018, 115, 8-13.	0.5	65
21	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. BJU International, 2018, 121, 619-626.	1.3	70
22	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.2	86
23	Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. Journal of Urology, 2018, 199, 161-171.	0.2	188
24	Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy. Journal of Urology, 2018, 200, 1068-1074.	0.2	15
25	High ϕ . journal of applied laboratory medicine, The, 2018, 3, 333-335.	0.6	0
26	Where it all Began. Journal of Urology, 2017, 197, S153.	0.2	0
27	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. Journal of Urology, 2017, 197, 1245-1250.	0.2	16
28	Prostate Health Index density improves detection of clinically significant prostate cancer. BJU International, 2017, 120, 793-798.	1.3	69
29	Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men. Urology, 2017, 104, 143-149.	0.5	4
30	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	1.2	41
31	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	0.9	256
32	Risk factors for metastatic prostate cancer: A sentinel event case series. Prostate, 2017, 77, 1366-1372.	1.2	2
33	Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU International, 2017, 120, 61-68.	1.3	71
34	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017, 197, 1060-1067.	0.2	10
35	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. European Urology, 2017, 71, 907-912.	0.9	44
36	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. BJU International, 2017, 119, 444-448.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. <i>BJU International</i> , 2017, 119, 676-683.	1.3	86
38	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	0.8	20
39	PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5075-5075.	0.8	2
40	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5077-5077.	0.8	12
41	Best of the 2017 AUA Annual Meeting: Highlights From the 2017 American Urological Association Annual Meeting, May 12-16, 2017, Boston, MA. <i>Reviews in Urology</i> , 2017, 19, 169-179.	0.9	3
42	Risk factors for metastatic prostate cancer: A sentinel event case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, 235-235.	0.8	0
43	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. <i>Journal of Urology</i> , 2016, 196, 1436-1444.	0.2	38
44	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. <i>Urology Case Reports</i> , 2016, 6, 45-46.	0.1	0
45	Role of biobanking in urology: a review. <i>BJU International</i> , 2016, 118, 864-868.	1.3	6
46	An Approach Using PSA Levels of 1.5â€µng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016, 96, 116-120.	0.5	11
47	Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. <i>Prostate</i> , 2016, 76, 1078-1087.	1.2	74
48	Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. <i>Urology</i> , 2016, 90, 136-140.	0.5	18
49	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	0.9	23
50	Urinary Biomarkers for Prostate Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 17-38.	0.8	39
51	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. <i>Journal of Urology</i> , 2016, 195, 337-342.	0.2	43
52	Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?. <i>Journal of Urology</i> , 2016, 195, 330-336.	0.2	14
53	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	0.9	206
54	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0146189.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease.. Journal of Clinical Oncology, 2016, 34, 51-51.	0.8	0
56	PSA doubling time (PSADT) \leq 6 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET).. Journal of Clinical Oncology, 2016, 34, e16587-e16587.	0.8	1
57	Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection. Cancer Biomarkers, 2015, 15, 763-773.	0.8	7
58	Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Therapeutic Advances in Urology, 2015, 7, 378-387.	0.9	91
59	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	0.9	47
60	Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU International, 2015, 115, 216-222.	1.3	25
61	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. European Urology, 2015, 68, 311-316.	0.9	5
62	¹⁸ F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1003-1010.	2.8	180
63	Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification. Urology, 2015, 85, 161-164.	0.5	71
64	The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. Journal of Urology, 2015, 193, 1163-1169.	0.2	228
65	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. Reviews in Urology, 2015, 17, 179-89.	0.9	0
66	Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. BJU International, 2014, 113, 561-567.	1.3	17
67	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. Urology, 2014, 84, 1434-1441.	0.5	56
68	Modeling grade progression in an active surveillance study. Statistics in Medicine, 2014, 33, 930-939.	0.8	41
69	Robotic Prostatectomy Diffusion Safety Concerns. JAMA Surgery, 2014, 149, 852.	2.2	1
70	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. Journal of Urology, 2014, 192, 1081-1087.	0.2	196
71	Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. BJU International, 2014, 114, E120-E129.	1.3	20
72	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate, 2014, 74, 628-636.	1.2	24

#	ARTICLE	IF	CITATIONS
73	Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. <i>Journal of Urology</i> , 2014, 191, 559-561.	0.2	0
74	Know your nomograms. <i>BJU International</i> , 2014, 113, 849-849.	1.3	2
75	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	0.8	234
76	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	9.4	408
77	Obesity and Long-Term Survival after Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 192, 1100-1104.	0.2	47
78	Predicting the Risk of Non-organ-confined Prostate Cancer When Perineural Invasion Is Found on Biopsy. <i>Urology</i> , 2014, 83, 1117-1121.	0.5	9
79	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5036-5036.	0.8	0
80	Best of the 2014 AUA Annual Meeting: Highlights From the 2014 American Urological Association Annual Meeting, May 16-21, 2014, Orlando, FL. <i>Reviews in Urology</i> , 2014, 16, 139-44.	0.9	2
81	An updated prostate cancer staging nomogram (artin tables) based on cases from 2006 to 2011. <i>BJU International</i> , 2013, 111, 22-29.	1.3	323
82	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. <i>Journal of Urology</i> , 2013, 190, 1218-1223.	0.2	89
83	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. <i>European Urology</i> , 2013, 63, 201-209.	0.9	114
84	Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 589-594.	0.8	4
85	Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. <i>Journal of Urology</i> , 2013, 189, 1702-1706.	0.2	51
86	Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. <i>BJU International</i> , 2013, 111, 1037-1045.	1.3	95
87	Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. <i>BJU International</i> , 2013, 111, 753-760.	1.3	540
88	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. <i>Journal of Urology</i> , 2013, 190, 2068-2073.	0.2	13
89	Early Detection of Prostate Cancer Continues to Support Rational, Limited Screening. <i>Journal of Urology</i> , 2013, 190, 427-428.	0.2	4
90	African American Men With Very Low-Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2991-2997.	0.8	220

#	ARTICLE	IF	CITATIONS
91	Genetic tests for prostate cancer. <i>Reviews in Urology</i> , 2013, 15, 208-9.	0.9	2
92	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4294-4296.	0.8	162
93	Radical Prostatectomy Outcome in Men 65 Years Old or Older With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2012, 187, 1620-1625.	0.2	20
94	High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core is Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgical Margins at Prostatectomy. <i>Urology</i> , 2012, 79, 863-868.	0.5	9
95	Germline Mutations in <i>HOXB13</i> and Prostate-Cancer Risk. <i>New England Journal of Medicine</i> , 2012, 366, 141-149.	13.9	566
96	Association of 25 OH-proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 1131-1136.	0.2	115
97	Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. <i>Prostate</i> , 2012, 72, 966-976.	1.2	13
98	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. <i>BJU International</i> , 2012, 109, 32-39.	1.3	221
99	Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. <i>BJU International</i> , 2012, 109, 988-993.	1.3	22
100	Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA TM , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study. <i>BJU International</i> , 2012, 109, 1770-1775.	1.3	17
101	Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. <i>BJU International</i> , 2012, 110, 1122-1128.	1.3	39
102	Impact of surgical margin status on prostate-cancer-specific mortality. <i>BJU International</i> , 2012, 110, 1684-1689.	1.3	82
103	Radical Retropubic and Perineal Prostatectomy. , 2012, , 2801-2829.e4.		8
104	Prostate Cancer Tumor Markers. , 2012, , 2748-2762.e6.		6
105	A Multicenter Study of 25 OH-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. <i>Journal of Urology</i> , 2011, 185, 1650-1655.	0.2	408
106	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 1691-1697.	0.2	70
107	ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program. <i>Urology</i> , 2011, 77, 763.e1-763.e6.	0.5	47
108	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 869-875.	0.2	574

#	ARTICLE	IF	CITATIONS
109	Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. <i>BJU International</i> , 2011, 107, 1562-1569.	1.3	36
110	Obesity and prostate enlargement in men with localized prostate cancer. <i>BJU International</i> , 2011, 108, 1750-1755.	1.3	22
111	Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. <i>World Journal of Urology</i> , 2011, 29, 11-14.	1.2	6
112	Fifth-Generation Digital Immunoassay for Prostate-Specific Antigen by Single Molecule Array Technology. <i>Clinical Chemistry</i> , 2011, 57, 1712-1721.	1.5	55
113	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. <i>Modern Pathology</i> , 2011, 24, 1511-1520.	2.9	57
114	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 2185-2190.	0.8	545
115	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 6563-6573.	3.2	309
116	Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. <i>Reviews in Urology</i> , 2011, 13, e191-5.	0.9	18
117	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010, 57, e2-e3.	0.9	6
118	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. <i>BJU International</i> , 2010, 106, 1612-1617.	1.3	13
119	A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [α -2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1193-1200.	1.1	186
120	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. <i>Journal of Clinical Oncology</i> , 2010, 28, 2810-2816.	0.8	237
121	Validation of the Partin Nomogram for Prostate Cancer in a National Sample. <i>Journal of Urology</i> , 2010, 183, 105-111.	0.2	47
122	Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. <i>Journal of Urology</i> , 2010, 183, 534-538.	0.2	119
123	Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. <i>Urology</i> , 2010, 76, 715-721.	0.5	55
124	Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. <i>Urology</i> , 2010, 76, 553-557.	0.5	77
125	Tumor Grade at Margins of Resection in Radical Prostatectomy Specimens Is an Independent Predictor of Prognosis. <i>Urology</i> , 2010, 76, 1206-1209.	0.5	83
126	PCA3 Urinary Biomarker for Prostate Cancer. <i>Reviews in Urology</i> , 2010, 12, e205-6.	0.9	3

#	ARTICLE	IF	CITATIONS
127	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. <i>Journal of Clinical Oncology</i> , 2009, 27, 4986-4993.	0.8	57
128	Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 16-22.	0.4	939
129	Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7316-7321.	3.2	57
130	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>European Urology</i> , 2009, 56, 659-668.	0.9	161
131	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. <i>Prostate</i> , 2009, 69, 1195-1205.	1.2	93
132	Biomarkers for Prostate Cancer. <i>Annual Review of Medicine</i> , 2009, 60, 139-151.	5.0	180
133	DNA Ploidy as Surrogate for Biopsy Gleason Score for Preoperative Organ Versus Nonorgan-confined Prostate Cancer Prediction. <i>Urology</i> , 2009, 73, 1092-1097.	0.5	15
134	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. <i>Journal of Urology</i> , 2009, 182, 491-498.	0.2	18
135	Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer. , 2009, , 79-95.		0
136	Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. <i>Prostate</i> , 2008, 68, 183-189.	1.2	25
137	Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. <i>Prostate</i> , 2008, 68, 691-697.	1.2	41
138	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. <i>Prostate</i> , 2008, 68, 1257-1262.	1.2	47
139	Long-term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. <i>Prostate</i> , 2008, 68, 1806-1815.	1.2	31
140	Prognostic value of Her2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. <i>International Journal of Cancer</i> , 2008, 123, 2636-2643.	2.3	21
141	Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. <i>Nature Genetics</i> , 2008, 40, 1153-1155.	9.4	158
142	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. <i>Nature Genetics</i> , 2008, 40, 281-283.	9.4	357
143	Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 767-776.	0.9	77
144	CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 179, 529-535.	0.2	68

#	ARTICLE	IF	CITATIONS
145	Prostate Specific Antigen Versus Prostate Specific Antigen Density as a Prognosticator of Pathological Characteristics and Biochemical Recurrence Following Radical Prostatectomy. Journal of Urology, 2008, 179, 1780-1784.	0.2	30
146	The Natural History of Men Treated With Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical Prostatectomy. Journal of Urology, 2008, 179, 156-162.	0.2	60
147	[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study. Journal of Urology, 2008, 180, 539-543.	0.2	98
148	PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. Journal of Urology, 2008, 179, 1587-1592.	0.2	404
149	Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease. Clinical Cancer Research, 2008, 14, 5819-5824.	3.2	61
150	Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. JAMA - Journal of the American Medical Association, 2008, 299, 2760.	3.8	586
151	The Role of Complexed Prostate-Specific Antigen in Prostate Cancer Screening. , 2008, , 29-41.		1
152	Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP. Journal of the National Cancer Institute, 2007, 99, 1836-1844.	3.0	235
153	Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans. Journal of the National Cancer Institute, 2007, 99, 1525-1533.	3.0	126
154	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. Clinical Cancer Research, 2007, 13, 5361-5367.	3.2	82
155	Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. JAMA - Journal of the American Medical Association, 2007, 298, 2275.	3.8	291
156	Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. Journal of Clinical Oncology, 2007, 25, 1765-1771.	0.8	177
157	Do Racial Differences in Prostate Size Explain Higher Serum Prostate-Specific Antigen Concentrations Among Black Men?. Urology, 2007, 69, 1138-1142.	0.5	19
158	Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005. Urology, 2007, 69, 1095-1101.	0.5	410
159	Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. Journal of Urology, 2007, 177, 1777-1781.	0.2	45
160	Radical prostatectomy for clinical stage T3a disease. Cancer, 2007, 109, 1273-1278.	2.0	140
161	Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate, 2007, 67, 1202-1210.	1.2	23
162	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nature Genetics, 2007, 39, 631-637.	9.4	818

#	ARTICLE	IF	CITATIONS
163	Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. <i>Reviews in Urology</i> , 2007, 9, 133-54.	0.9	2
164	Black Race Does Not Independently Predict Adverse Outcome Following Radical Retropubic Prostatectomy at a Tertiary Referral Center. <i>Journal of Urology</i> , 2006, 176, 515-519.	0.2	34
165	Pathological Outcomes and Biochemical Progression in Men With T1c Prostate Cancer Undergoing Radical Prostatectomy With Prostate Specific Antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. <i>Journal of Urology</i> , 2006, 176, 554-558.	0.2	28
166	Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2006, 176, 1404-1408.	0.2	110
167	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. <i>Urology</i> , 2006, 67, 115-119.	0.5	34
168	Prostate-Specific Antigen: Update 2006. <i>Urology</i> , 2006, 67, 458-460.	0.5	24
169	Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. <i>Cancer</i> , 2006, 107, 1265-1272.	2.0	102
170	Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry" <i>International Journal of Cancer</i> , 2006, 118, 785-785.	2.3	3
171	Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2351.	3.8	360
172	Metabolic Factors Associated with Benign Prostatic Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2562-2568.	1.8	281
173	The predictive capability of prostate-specific antigen kinetics. <i>Reviews in Urology</i> , 2006, 8, 41-3.	0.9	0
174	The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. <i>Reviews in Urology</i> , 2006, 8, 112-9.	0.9	16
175	Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate. <i>Reviews in Urology</i> , 2006, 8, 232-4.	0.9	0
176	Surgical margin status after radical retropubic prostatectomy. <i>BJU International</i> , 2005, 95, 281-284.	1.3	14
177	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4037-4043.	3.2	198
178	Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 433.	3.8	1,186
179	COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE. <i>Journal of Urology</i> , 2005, 173, 752-756.	0.2	25
180	THE PROSTATIC SPECIFIC ANTIGEN ERA IS ALIVE AND WELL: PROSTATIC SPECIFIC ANTIGEN AND BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1276-1281.	0.2	67

#	ARTICLE	IF	CITATIONS
181	Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen. <i>Urology</i> , 2005, 66, 577-581.	0.5	6
182	OBESITY AND CAPSULAR INCISION AT THE TIME OF OPEN RETROPUBIC RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1798-1801.	0.2	91
183	Docetaxel in androgen-independent prostate cancer: an update. <i>BJU International</i> , 2004, 94, 1209-1210.	1.3	4
184	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. <i>Current Prostate Reports</i> , 2004, 2, 12-20.	0.1	0
185	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. <i>Current Urology Reports</i> , 2004, 5, 179-187.	1.0	20
186	Characteristics of insignificant clinical T1c prostate tumors. <i>Cancer</i> , 2004, 101, 2001-2005.	2.0	213
187	Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. <i>Cancer</i> , 2004, 101, 2549-2556.	2.0	61
188	Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed Population. <i>Journal of Urology</i> , 2004, 171, 1782-1787.	0.2	65
189	An Evaluation of the Decreasing Incidence of Positive Surgical Margins in a Large Retropubic Prostatectomy Series. <i>Journal of Urology</i> , 2004, 171, 23-26.	0.2	133
190	Applying complexed prostate-specific antigen to clinical practice. <i>Urology</i> , 2004, 63, 815-818.	0.5	15
191	Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. <i>Urology</i> , 2004, 64, 551-555.	0.5	76
192	Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. <i>Urology</i> , 2004, 64, 765-771.	0.5	46
193	Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. <i>Urology</i> , 2004, 64, 1160-1164.	0.5	49
194	Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2. , 2004, , 15-36.		0
195	IL-3 PSA Update-2004. <i>Japanese Journal of Urology</i> , 2004, 95, 267.	0.0	0
196	Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma. <i>Cancer</i> , 2003, 97, 969-978.	2.0	29
197	A neurocomputational model for prostate carcinoma detection. <i>Cancer</i> , 2003, 98, 1849-1854.	2.0	37
198	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?. <i>Journal of Urology</i> , 2003, 170, 2274-2278.	0.2	71

#	ARTICLE	IF	CITATIONS
199	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 517-523.	0.2	691
200	Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial. <i>Journal of Urology</i> , 2003, 170, 1787-1791.	0.2	109
201	PSA markers in prostate cancer detection. <i>Urologic Clinics of North America</i> , 2003, 30, 677-686.	0.8	81
202	Comparison of Total Prostate-Specific Antigen and Derivative Levels in a Screening Population of Black, White, and Korean-American Men. <i>Clinical Prostate Cancer</i> , 2003, 2, 173-176.	2.1	3
203	Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. <i>Urology</i> , 2003, 62, 1058-1062.	0.5	11
204	Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. <i>Urology</i> , 2003, 62, 2-8.	0.5	35
205	Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. <i>Urology</i> , 2003, 61, 274-276.	0.5	106
206	Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. <i>Urology</i> , 2003, 62, 177-181.	0.5	63
207	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. <i>Urology</i> , 2003, 62, 86-91.	0.5	117
208	Probability of biochemical recurrence by analysis of pathologic stage, gleason score, and margin status for localized prostate cancer. <i>Urology</i> , 2003, 62, 866-871.	0.5	75
209	The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer. <i>Journal of Urology</i> , 2003, 170, 1709-1716.	0.2	42
210	Evaluation of Proprostate Specific Antigen for Early Detection of Prostate Cancer in Men With a Total Prostate Specific Antigen Range of 4.0 to 10.0 Ng/Ml. <i>Journal of Urology</i> , 2003, 170, 723-726.	0.2	79
211	Management of High-Risk Populations with Locally Advanced Prostate Cancer. <i>Oncologist</i> , 2003, 8, 259-269.	1.9	34
212	Standardization of Two Immunoassays for Human Glandular Kallikrein 2. <i>Clinical Chemistry</i> , 2003, 49, 601-610.	1.5	23
213	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. <i>Journal of Urology</i> , 2003, 169, 517-23.	0.2	271
214	The Clinical Management of Prostate Cancer – The Surgeon's Approach and Outcomes. , 2003, , 811-831.		0
215	Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. <i>Reviews in Urology</i> , 2003, 5, 111-7.	0.9	0
216	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. <i>Journal of Urology</i> , 2002, 167, 2440-2442.	0.2	90

#	ARTICLE	IF	CITATIONS
217	Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. <i>Urology</i> , 2002, 59, 85-90.	0.5	52
218	Free prostate-specific antigen in serum is becoming more complex. <i>Urology</i> , 2002, 59, 797-802.	0.5	174
219	Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. <i>Urology</i> , 2002, 60, 18-23.	0.5	12
220	Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. <i>Urology</i> , 2002, 60, 31-35.	0.5	62
221	Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. <i>Urology</i> , 2002, 60, 47-52.	0.5	34
222	Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?. <i>Urology</i> , 2002, 60, 36-41.	0.5	11
223	Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. <i>Urology</i> , 2002, 60, 10-17.	0.5	21
224	Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. <i>Urology</i> , 2002, 60, 24-30.	0.5	27
225	Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. <i>Urology</i> , 2002, 60, 1034-1039.	0.5	29
226	PSA Levels and the Probability of Prostate Cancer on Biopsy. <i>European Urology Supplements</i> , 2002, 1, 21-27.	0.1	35
227	Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range. <i>Journal of Urology</i> , 2002, 168, 504-508.	0.2	36
228	Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of Aging. <i>Journal of Urology</i> , 2002, 167, 2484-2487.	0.2	56
229	Prediction of Pathological Stage in Patients with Clinical Stage T1c Prostate Cancer: The New Challenge. <i>Journal of Urology</i> , 2002, 168, 100-104.	0.2	27
230	Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage. <i>Clinical Chemistry</i> , 2002, 48, 1828-1834.	1.5	33
231	Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. <i>Cancer</i> , 2002, 94, 987-996.	2.0	86
232	Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. <i>Cancer</i> , 2002, 95, 1016-1021.	2.0	54
233	Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. <i>Nature Genetics</i> , 2002, 32, 321-325.	9.4	318
234	Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. <i>Cancer</i> , 2002, 94, 987-996.	2.0	1

#	ARTICLE	IF	CITATIONS
235	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 + 3 and 3 + 4 Independent of the Number of Involved Cores?. Journal of Urology, 2002, , 2440-2442.	0.2	4
236	Prediction of Pathological Stage in Patients with Clinical Stage T1c Prostate Cancer: The New Challenge. Journal of Urology, 2002, , 100-104.	0.2	3
237	Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range. Journal of Urology, 2002, , 504-508.	0.2	4
238	Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer. Reviews in Urology, 2002, 4, 198-200.	0.9	1
239	Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. Journal of Urology, 2002, 167, 2440-2.	0.2	27
240	Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology, 2002, 16, 1024-38, 1042; discussion 1042, 1047-8, 1051.	0.4	15
241	Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology, 2002, 16, 1218-24; discussion 1224, 1227-8 passim.	0.4	9
242	Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents. Urology, 2001, 57, 132-136.	0.5	5
243	The role of prostate needle biopsy in evaluation of chemopreventive agents. Urology, 2001, 57, 191-193.	0.5	5
244	Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology, 2001, 57, 481-485.	0.5	64
245	Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology, 2001, 57, 707-711.	0.5	28
246	Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology, 2001, 57, 1105-1111.	0.5	53
247	Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology, 2001, 57, 1033-1037.	0.5	76
248	Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology, 2001, 57, 1100-1104.	0.5	59
249	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. Urology, 2001, 58, 746-751.	0.5	71
250	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology, 2001, 58, 843-848.	0.5	943
251	INDICATORS OF PATHOLOGIC STAGE OF PROSTATE CANCER AND THEIR USE IN CLINICAL PRACTICE. Urologic Clinics of North America, 2001, 28, 443-458.	0.8	19
252	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 555-565.	0.8	939

#	ARTICLE	IF	CITATIONS
253	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. <i>Journal of Urology</i> , 2001, 165, 864-866.	0.2	30
254	Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer. <i>Clinical Chemistry</i> , 2001, 47, 1924-1926.	1.5	17
255	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. <i>Cancer</i> , 2001, 91, 1661-1666.	2.0	62
256	Prediction of prostate carcinoma stage by quantitative biopsy pathology. <i>Cancer</i> , 2001, 91, 2322-2328.	2.0	31
257	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. <i>Cancer</i> , 2001, 91, 1661-1666.	2.0	43
258	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. <i>Journal of Urology</i> , 2001, , 864-866.	0.2	2
259	The Prognostic Significance of Tertiary Gleason Patterns of Higher Grade in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2000, 24, 563-569.	2.1	195
260	Diagnosis of localized prostate cancer: 10 years of progress. <i>Current Opinion in Urology</i> , 2000, 10, 319-327.	0.9	12
261	Report on Prostate Cancer Tumor Marker Workshop 1999. <i>Cancer</i> , 2000, 88, 955-963.	2.0	11
262	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. <i>Cancer</i> , 2000, 89, 2577-2586.	2.0	37
263	Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations. <i>Journal of Cellular Biochemistry</i> , 2000, 79, 151-157.	1.2	53
264	Needle Biopsy of Recurrent Adenocarcinoma of the Prostate After Radical Prostatectomy. <i>Modern Pathology</i> , 2000, 13, 521-527.	2.9	6
265	Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer?. <i>Current Urology Reports</i> , 2000, 1, 245-245.	1.0	4
266	What does prostate-specific antigen recurrence mean?. <i>Current Urology Reports</i> , 2000, 1, 28-35.	1.0	9
267	The role of free prostate-specific antigen in prostate cancer detection. <i>Current Urology Reports</i> , 2000, 1, 78-82.	1.0	6
268	Prediction of locoregional extension and metastatic disease in prostate cancer: a review. <i>World Journal of Urology</i> , 2000, 18, 165-172.	1.2	17
269	Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. <i>Urology</i> , 2000, 55, 909-914.	0.5	25
270	Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. <i>Urology</i> , 2000, 56, 255-260.	0.5	275

#	ARTICLE	IF	CITATIONS
271	Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. <i>Urology</i> , 2000, 56, 283-288.	0.5	148
272	Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. <i>Urology</i> , 2000, 56, 823-827.	0.5	298
273	A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. <i>Urology</i> , 2000, 56, 994-999.	0.5	69
274	Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. <i>Urology</i> , 2000, 55, 372-376.	0.5	47
275	CORRELATION OF SERUM PROSTATE SPECIFIC ANTIGEN AND QUANTITATIVE IMMUNOHISTOCHEMISTRY. <i>Journal of Urology</i> , 2000, 163, 1739-1742.	0.2	42
276	COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 163, 1476-1480.	0.2	137
277	EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2000, 163, 1451-1456.	0.2	128
278	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. <i>Journal of Urology</i> , 2000, 164, 89-92.	0.2	56
279	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 164, 1591-1595.	0.2	160
280	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. , 2000, 89, 2577.		1
281	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. <i>Journal of Urology</i> , 2000, , 89-92.	0.2	1
282	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, , 1591-1595.	0.2	3
283	Prostate cancer: Detection, staging, and treatment of localized disease. <i>Seminars in Roentgenology</i> , 1999, 34, 269-283.	0.2	7
284	Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet-WebGel. <i>Electrophoresis</i> , 1999, 20, 3492-3507.	1.3	18
285	Comparison of clinical staging algorithms and ¹¹¹ Indium-capromab pentetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. <i>Cancer</i> , 1999, 85, 1586-1592.	2.0	101
286	Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. <i>International Journal of Cancer</i> , 1999, 84, 594-597.	2.3	13
287	Critical analysis of false elevations in PSA results reported with the abbott AxSYM assay. , 1999, 38, 79-80.		0
288	Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate. , 1999, 39, 213-218.		57

#	ARTICLE	IF	CITATIONS
289	Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. , 1999, 39, 298-304.		100
290	INFLUENCE OF SEXTANT PROSTATE NEEDLE BIOPSY OR SURGERY ON THE DETECTION AND HARVEST OF INTACT CIRCULATING PROSTATE CANCER CELLS. Journal of Urology, 1999, 162, 749-752.	0.2	17
291	Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. Urology, 1999, 53, 1179-1183.	0.5	35
292	Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology, 1999, 54, 220-224.	0.5	117
293	Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology, 1999, 54, 839-845.	0.5	126
294	Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology, 1999, 54, 791-795.	0.5	78
295	DIGITAL RECTAL EXAMINATION AND IMAGING STUDIES ARE UNNECESSARY IN MEN WITH UNDETECTABLE PROSTATE SPECIFIC ANTIGEN FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1999, 162, 1337-1340.	0.2	55
296	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. Journal of Urology, 1999, 162, 1346-1351.	0.2	82
297	PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING. Journal of Urology, 1999, 162, 293-306.	0.2	530
298	Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology, 1999, 53, 175-179.	0.5	29
299	Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology, 1999, 53, 126-130.	0.5	123
300	MOLECULAR STAGING OF MEN WITH SEMINAL VESICLE INVASION AND NEGATIVE LYMPH NODES AT RADICAL PROSTATECTOMY. Journal of Urology, 1999, , 235.	0.2	4
301	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. Journal of Urology, 1999, , 1346-1351.	0.2	3
302	Automated image analysis system for detecting boundaries of live prostate cancer cells. , 1998, 31, 287-294.		26
303	ELEVATED PROSTATE-SPECIFIC ANTIGEN, ABNORMAL PROSTATE EVALUATION ON DIGITAL RECTAL EXAMINATION, AND TRANSRECTAL ULTRASOUND AND PROSTATE BIOPSY. Urologic Clinics of North America, 1998, 25, 581-589.	0.8	18
304	LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 159, 173-178.	0.2	200
305	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. Journal of Urology, 1998, 160, 660-663.	0.2	69
306	MINILAPAROTOMY RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 1998, 160, 2440-2445.	0.2	37

#	ARTICLE	IF	CITATIONS
307	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, 160, 97-101.	0.2	84
308	THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER. Journal of Urology, 1998, 159, 1238-1242.	0.2	99
309	INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 1998, 159, 449-453.	0.2	59
310	Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate. Critical Reviews in Clinical Laboratory Sciences, 1998, 35, 275-368.	2.7	269
311	An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology, 1998, 52, 455-461.	0.5	89
312	DIFFERENTIAL NUCLEAR MATRIX PROTEIN EXPRESSION IN PROSTATE CANCERS: CORRELATION WITH PATHOLOGIC STAGE. Journal of Urology, 1998, 159, 1354-1358.	0.2	31
313	INTERPRETATION OF FREE PROSTATE SPECIFIC ANTIGEN CLINICAL RESEARCH STUDIES FOR THE DETECTION OF PROSTATE CANCER. Journal of Urology, 1998, 159, 5-12.	0.2	204
314	Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease. JAMA - Journal of the American Medical Association, 1998, 279, 1542.	3.8	990
315	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, , 97-100.	0.2	1
316	Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic Hyperplasia. Journal of Urology, 1997, 157, 2171-2178.	0.2	71
317	Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 1997, 49, 379-384.	0.5	90
318	Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology, 1997, 50, 715-721.	0.5	37
319	Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 1997, 277, 1445.	3.8	1,060
320	PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. Urologic Clinics of North America, 1997, 24, 395-406.	0.8	542
321	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World Journal of Urology, 1997, 15, 373-377.	1.2	24
322	Heredity and prostate cancer: A study of World War II veteran twins. , 1997, 33, 240-245.		134
323	Comparison of serum PSMA, PSA levels with results of cytozen-356 ProstaScint® scanning in prostatic cancer patients. , 1997, 33, 281-285.		49
324	Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate. , 1997, 79, 772-779.		179

#	ARTICLE	IF	CITATIONS
325	Family history facilitates the early diagnosis of prostate carcinoma. , 1997, 80, 1871-1874.		48
326	Heredity and prostate cancer: A study of World War II veteran twins. , 1997, 33, 240.		3
327	Evaluation of Smooth Muscle and Collagen Subtypes in Normal Newborns and Those With Bladder Exstrophy. Journal of Urology, 1996, 156, 2034-2036.	0.2	66
328	THE USE OF PROSTATE-SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS OF LOCALIZED PROSTATE CANCER. Urologic Clinics of North America, 1996, 23, 531-540.	0.8	27
329	Serum Prostate Specific Antigen Levels after Transurethral Resection of Prostate: A Longitudinal Characterization in Men with Benign Prostatic Hyperplasia. Journal of Urology, 1996, 156, 1035-1039.	0.2	37
330	Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology, 1996, 48, 685-691.	0.5	46
331	Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology, 1996, 48, 45-50.	0.5	29
332	The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology, 1996, 48, 51-54.	0.5	57
333	Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and age. Urology, 1996, 48, 55-61.	0.5	226
334	Extended Followup of the Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer and Extensive Capsular Perforation. Journal of Urology, 1996, 156, 454-458.	0.2	79
335	Role of laparoscopy in the diagnosis and treatment of prostate cancer. , 1996, 12, 139-144.		11
336	Prediction of Progression Following Radical Prostatectomy. American Journal of Surgical Pathology, 1996, 20, 286-292.	2.1	532
337	OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology, 1995, 45, 81-86.	0.5	196
338	Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 1995, 45, 831-838.	0.5	179
339	Partial Nephrectomy: Technique Complications and Pathological Findings. Journal of Urology, 1995, 154, 1312-1318.	0.2	156
340	Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. Journal of Urology, 1995, 153, 1015-1019.	0.2	44
341	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate, 1994, 25, 249-265.	1.2	79
342	Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 1994, 43, 649-659.	0.5	376

#	ARTICLE	IF	CITATIONS
343	Small High Grade Adenocarcinoma of the Prostate in Radical Prostatectomy Specimens Performed for Nonpalpable Disease: Pathogenetic and Clinical Implications. <i>Journal of Urology</i> , 1994, 151, 1587-1592.	0.2	87
344	The Clinical Usefulness of Prostate Specific Antigen: Update 1994. <i>Journal of Urology</i> , 1994, 152, 1358-1368.	0.2	372
345	Re: The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer, by A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh, <i>J. Urol.</i> , 150: 110-115, 1993. <i>Journal of Urology</i> , 1994, 152, 172-173.	0.2	25
346	Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years. <i>Journal of Urology</i> , 1994, 152, 1831-1836.	0.2	650
347	The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. <i>Prostate</i> , 1993, 22, 39-42.	1.2	80
348	The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer. <i>Journal of Urology</i> , 1993, 150, 110-114.	0.2	1,152
349	Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup. <i>Journal of Urology</i> , 1993, 149, 1478-1481.	0.2	314
350	SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 1993, 20, 713-725.	0.8	451
351	A Quantitative Histological Analysis of the Dilated Ureter of Childhood. <i>Journal of Urology</i> , 1992, 148, 1482-1486.	0.2	46
352	Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. <i>Cancer</i> , 1992, 70, 161-168.	2.0	107
353	Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia. <i>Journal of Urology</i> , 1990, 143, 747-752.	0.2	568
354	The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer. <i>Journal of Urology</i> , 1990, 144, 1167-1170.	0.2	41
355	Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. <i>Cancer</i> , 1990, 65, 1021-1027.	2.0	52
356	Morphometric Measurement of Tumor Volume and Per Cent of Gland Involvement as Predictors of Pathological Stage in Clinical Stage B Prostate Cancer. <i>Journal of Urology</i> , 1989, 141, 341-345.	0.2	168